GEP-NETs update: Biotherapy for neuroendocrine tumours

Area of Science:

• Oncology
• Endocrinology
• Immunology

Background:

• Neuroendocrine tumours (NETs) are rare and diverse, with limited effective treatments historically.
• Chemotherapy has shown disappointing results for NETs.
• Biotherapy, including somatostatin analogues (SSAs) and interferon alpha, has emerged as a key treatment modality.

Purpose of the Study:

• To review the evolving therapeutic landscape for neuroendocrine tumours (NETs).
• To highlight advancements in biotherapy, including novel somatostatin analogues and immunotherapies.
• To discuss future directions in NET treatment strategies.

Main Methods:

• Review of current literature on neuroendocrine tumour (NET) treatments.
• Analysis of the mechanisms of action for somatostatin analogues (SSAs) and immunotherapies.
• Discussion of emerging therapeutic agents and combinations.

Main Results:

• Somatostatin analogues (SSAs) improve symptomatic relief and tumour control in NETs.
• Novel SSAs, chimeric molecules, and targeted agents (mTOR inhibitors, antiangiogenic agents) show promise.
• Immunotherapy, while effective, has limitations due to adverse events; novel checkpoint inhibitors are under investigation.

Conclusions:

• Biotherapy is a cornerstone for initial NET treatment.
• Further research is needed for patient selection, molecular profiling, and optimizing treatment sequences and combinations.
• Development of novel biotherapy agents is ongoing.